3 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 3, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
Follow Sexual Infantilism: new trials by email Literature Review of Sexual Infantilism trials Research Report on Sexual Infantilism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years Semaglutide (Wegovy) weekly injection, Placebo weekly Injection - Craniopharyngioma, Child | Phase 3 | Not yet recruiting | University Hospital, Angers | 50 | 2026-12-01 | 2026-11-19 |
| A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) Setmelanotide, Placebo - Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form | Phase 3 | Recruiting | Rhythm Pharmaceuticals, Inc. | 39 | 2025-09-23 | 2026-02-12 |
| Open-Label Extension Study of Setmelanotide Setmelanotide - Obesity Associated With Defects in Leptin-melanocortin Pathway | Phase 3 | Completed | Rhythm Pharmaceuticals, Inc. | 28 | 2024-10-21 | 2026-07-15 |
| A Trial of Setmelanotide in Acquired Hypothalamic Obesity Setmelanotide, Placebo - Hypothalamic Obesity | Phase 3 | Active not recruiting | Rhythm Pharmaceuticals, Inc. | 143 | 2023-04-26 | 2026-08-10 |
| Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy Exenatide, Placebo - Craniopharyngiomas, Hypothalamic Obesity | Phase 3 | Completed | University Hospital, Bordeaux | 42 | 2017-01-11 | 2026-05-22 |
| Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity Exenatide, placebo - Hypothalamic Obesity | Phase 3 | Completed | Seattle Children's Hospital | 42 | 2016-03-01 | 2022-05-05 |
Craniopharyngioma (2) · Obesity (2) · Optic Nerve Hypoplasia (1) · Septo-Optic Dysplasia (1) · Weight Loss (1)
Congenital Abnormalities (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Disorders of Sex Development (6) · Endocrine System Diseases (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Gonadal Disorders (6) · Gonadal Dysgenesis (6) · Hypogonadism (6) · Male Urogenital Diseases (6) · Urogenital Abnormalities (6) · Urogenital Diseases (6) · Body Weight (2) · Neoplasms (2) · Neoplasms by Histologic Type (2)
setmelanotide (3) · Exenatide (2) · semaglutide (1)
Rhythm Pharmaceuticals, Inc. (3) · Seattle Children's Hospital (1) · University Hospital, Angers (1) · University Hospital, Bordeaux (1)
United States (4) · France (2) · United Kingdom (2) · Canada (1) · Germany (1) · Japan (1) · Netherlands (1)
David Meeker, MD (3) · Blandine Gatta-Cherifi, Pr (1) · Christian Roth, MD (1) · Paul Perez, Dr (1)